Perioperative use proves elusive for Tecentriq
Adjuvant and neoadjuvant settings are an important target for Roche’s Tecentriq, but how likely is the drug to become broadly applicable?
Another Alzheimer’s failure for Biogen bulls to shrug off
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Another chance for Lilly and Roche to take on Alzheimer's
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
Forty Seven bucks the trend
Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.
Morphosys gets a major tafasitamab endorsement
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Surprise! There’s a tumour in which Keytruda doesn’t work
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Why a 2020 spotlight will fall on tafasitamab
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Glaxo’s myeloma Dreamm turns into a nightmare
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.
Ash 2019 – for Car-T the bispecific antibody threat is real
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.